(Q51580843)

English

A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment.

scientific article published in July 1996

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

1 reference

based on heuristic

inferred from title

author name string

Mukherjee T

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

Barad D

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

Turk R

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

Freeman R

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

language of work or name

0 references

publication date

1 July 1996

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

American Journal of Obstetrics and Gynecology

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

175

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

105-109

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Interval bone mineral density with long-term gonadotropin-releasing hormone agonist suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2896%2970258-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9378(96)70258-2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/8694034

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51580843&oldid=1384207826"